

Product Datasheet

P2Y12/P2RY12 Antibody (1C2A9) - BSA Free NBP2-61749

Unit Size: 0.1 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 1

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-61749

Updated 9/9/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP2-61749



NBP2-61749

P2Y12/P2RY12 Antibody (1C2A9) - BSA Free


Product Information	
Unit Size	0.1 ml
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Monoclonal
Clone	1C2A9
Preservative	0.05% Sodium Azide
Isotype	IgG1
Purity	Protein G purified
Buffer	PBS
Target Molecular Weight	39.4 kDa

Product Description	
Description	Novus Biologicals Mouse P2Y12/P2RY12 Antibody (1C2A9) - BSA Free (NBP2-61749) is a monoclonal antibody validated for use in WB, ELISA and Flow. Anti-P2Y12/P2RY12 Antibody: Cited in 1 publication. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Mouse
Gene ID	64805
Gene Symbol	P2RY12
Species	Human
Immunogen	Purified recombinant fragment of human P2Y12/P2RY12 (AA: extra mix) expressed in E. Coli.


Product Application Details	
Applications	Western Blot, ELISA, Flow Cytometry
Recommended Dilutions	Western Blot 1:100-1:2000, Flow Cytometry 1:10-1:1000, ELISA 1:100-1:2000

Images


Western Blot: P2Y12/P2RY12 Antibody (1C2A9) [NBP2-61749] - Analysis using P2RY12 mAb against HEK293 (1) and P2RY12 (AA: extra mix)-hlgGFc transfected HEK293 (2) cell lysate.




Flow Cytometry: P2Y12/P2RY12 Antibody (1C2A9) [NBP2-61749] - Analysis of Hela cells using P2RY12 mouse mAb (green) and negative control (red).




Western Blot: P2Y12/P2RY12 Antibody (1C2A9) [NBP2-61749] - Analysis using P2RY12 mAb against human P2RY12 (AA: extra mix) recombinant protein. (Expected MW is 9.4 kDa)




Western Blot: P2Y12/P2RY12 Antibody (1C2A9) [NBP2-61749] - Analysis using P2RY12 mouse mAb against PC-3 (1) and C6 (2) cell lysate.




ELISA: P2Y12/P2RY12 Antibody (1C2A9) [NBP2-61749] - Black line: Control Antigen (100 ng); Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)



P2Y12 regulates EGFR activation, SLUG and ZEB1 expression and enhances PDAC cells viability. (A) Immunoblots showing the expression of P2Y12, p-EGFR Y1068, EGFR, SLUG and ZEB1 in AsPC-1 and BxPC-3 after P2Y12-specific siRNA treatment. Cancer cells were seeded and treated with P2Y12 siRNA or a negative control siRNA, as described in the Methods and Materials section. (B) The columns represent the fold change of protein levels (p-EGFR Y1068, SLUG and ZEB1) relative to the negative control siRNA-treated cells, normalised to 1 ($n \geq 3$). Statistical analysis was performed using one sample t-test (GraphPad Prism 8) comparing the mean of siP2Y12 treatment with the normalised value 1. (C) Cell viability of AsPC-1 and BxPC-3 cells following knockdown of P2Y12 compared with the negative control siRNA-treated cells ($n \geq 3$), calculated using one sample t-test (Graphpad Prism 8) and the normalised control group mean of 100%. Data are presented as mean \pm SEM. *** $p < 0.001$, ** $p < 0.002$, * $p < 0.033$. siNeg: siRNA negative control. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/31968611>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



The P2Y12 receptor, activated by ADP, triggers AKT activation in PDAC cells. (A) Immunoblots show the expression of P2Y12 and EGFR in PDAC cells (AsPC-1, BxPC-3, MiaPaCa-2, CFPAC-1 and PANC-1) and the normal pancreatic duct cells h-TERT-HPNE. Platelets were used as a positive control for P2Y12. Cells were seeded at 3×10^5 cells/well in a 6-well plate for 24 h, then washed, lysed and the proteins were collected and quantified. (B,C) Relative P2Y12 and EGFR expression in five PDAC cell lines and h-TERT-HPNE cells. The expression level was quantified and normalised to the loading control, α -actinin, with automated software Image Lab (version 5.1, BioRad, Hercules CA, USA) and represented as columns using GraphPad Prism 8 (GraphPad Software, Inc, CA, USA). (D) The P2Y12 inhibitor, ticagrelor, reduced ADP-induced AKT activation in AsPC-1 and BxPC-3. Briefly, cancer cells were seeded in a 12-well plate and after 24 h, cells were starved for 6 h, then treated with ticagrelor (5 μ M) combined with ADP (100 μ M) and the cells were further incubated for 30 min in serum-free media. The figure shows a representative blot from three independent experiments. (E) Extracellular ADP release from AsPC-1, BxPC-3, MiaPaCa-2 and h-TERT-HPNE. ADP was analysed in 250 μ L of PBS previously incubated with cells for 15 min as described in the Methods and Materials section. The columns represent the mean of relative fluorescence units (RFU) from three independent experiments. (F) Western blot analysis of phospho-EGFR Y1068 (p-EGFR Y1068), phospho-AKT S473 (p-AKT S473) and phospho-ERK 1/2 (p-ERK1/2) expression in lysates derived from AsPC-1, BxPC-3 and h-TERT-HPNE treated with ADP (10, 50 and 100 μ M) for 30 min. The figure shows a representative blot from three independent experiments. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/31968611>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Elaskalani O, Domenichini A, Abdol Razak NB et al. Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells Cancers (Basel) 2020-01-20 [PMID: 31968611]



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-61749

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF007	Goat anti-Mouse IgG Secondary Antibody [HRP]
NB7539	Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP]
NBP1-97005-0.5mg	Mouse IgG1 Isotype Control (MG1)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-61749

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

